

## CURRICULUM VITAE – CHRISTIAN WEBER

### GENERAL INFORMATION

Name: Univ.-Prof. Dr. med. Christian Weber, DoB 15<sup>th</sup> October, 1967  
Institute: Ludwig-Maximilians-Universität München (LMU Munich)  
Institute for Cardiovascular Prevention (IPEK)  
Department of Medicine, Klinikum der Universität München (KUM)  
Pettenkoferstr. 9, 80336 Munich, Germany  
Phone: +49 (0)89 4400 54350  
Email: [chweber@med.lmu.de](mailto:chweber@med.lmu.de)  
Web: <http://ipek.klinikum.uni-muenchen.de>

### ACADEMIC EDUCATION AND SCIENTIFIC DEGREES

2003 - 2004 Board Registration, Internal Medicine and Cardiology  
1999 Venia legend (habilitation) in Experimental Internal Medicine, LMU Munich  
1994 MD doctoral thesis (Dr. med.), LMU Munich  
1986 - 1993 Study of Medicine at LMU Munich, Germany

### SCIENTIFIC CAREER

2010 - present Chair in Preventative Vascular Medicine (W3) and Director, Institute for Cardiovascular Prevention (IPEK), LMU Munich  
2006 - present Adjunct Professor, Dept. Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands  
2005 - 2010 Chair of Molecular Cardiovascular Research (W3), Director, Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Germany  
2001 - 2005 Professor of Molecular Cardiology (C3), Fellow Cardiology, Medical Clinic I (Prof. Dr. P. Hanrath), RWTH Aachen University, Germany  
1997 - 2001 Fellow Internal Medicine, Medizinische Poliklinik (Prof. Dr. D. Schlöndorff), Group Leader DFG (*Deutsche Forschungsgemeinschaft*) Junior Research Group in Biosciences, LMU Munich  
1995 - 1997 Postdoctoral DFG Research Fellow, Center for Blood Research (Prof. Dr. T. Springer), Dept. Pathology, Harvard Medical School, Boston, USA  
1993 - 1994 Junior Fellow in Experimental Vascular Medicine, Institute for Cardiovascular Prevention (IPEK, Prof. Dr. P.C. Weber), LMU Munich

### KEY FIGURES

621 publications, 384 original articles (118 first/last author), 237 review articles  
*h*-index 103 / 105 / 126, total citations 38791 / 39881 / 58537 (Clarivate/Scopus/GoogleScholar)

## **COORDINATING FUNCTIONS, MEMBERSHIPS (selection)**

2021 -	Speaker, Munich Heart Alliance (MHA), German Centre for Cardiovasc. Res.
2018 - 2020	Chair, European Society of Cardiology (ESC) Council for Basic Cardiovascular Science (CBCS)
2019 - 2026	Principal Investigator of the DFG Excellence Cluster SyNergy
2018 - 2020	ESC Basic Science Council (Chair elect)
2014 - 2018	ESC Basic Science Council (Treasurer)
2011 - 2016	Coordinator, Leducq Transatlantic Network of Excellence <i>CVGeneF(x)</i>
2014 -	Speaker, DFG Collaborative Research Centre SFB1123 <i>Atherosclerosis mechanisms and networks of novel therapeutic targets</i>
2012 - 2014	Chair, ESC Working Group Atherosclerosis & Vascular Biology
2012 - 2022	Senior Associate Editor, <i>Arteriosclerosis Thrombosis &amp; Vascular Biology</i>
2011 - 2020	Co-Speaker, Munich Heart Alliance (MHA), partner site of the DZHK
2011	Member, International Society of Thrombosis & Haemostasis (ISTH, GTH)
2008 - 2010	Speaker, International Graduate School IRTG1508 <i>Arterial Remodeling</i>
2007 - 2014	Speaker, DFG program project grant FOR809 <i>Chemokines and adhesion molecules in cardiovascular pathogenesis</i>
2010 -	Editor-in-Chief <i>Thrombosis &amp; Haemostasis</i>
2007 - 2008	President, Society of Microcirculation and Vascular Biology (GfMVB)
2004 -	Member American Heart Association (AHA), Basic Science Council
2001 -	Member German Cardiac Society (DGK) and Fellow of the ESC (FESC)

## **AWARDS and HONORS (selection)**

2018, 2020	Designated as <i>Highly Cited Researcher</i> (Cross-Field) by Clarivate Analytics
2019	Elected Member of the National Academy of Science Leopoldina
2016	European Research Council (ERC) Advanced Grant <i>PROVASC</i>
2016 - 2021	Listed #1 in worldwide expert ranking on atherosclerosis (ExpertScape)
2015	Alexander-Schmidt-Award, Society of Thrombosis & Haemostasis (GTH)
2010	ERC Advanced Grant <i>Atheroprotect</i>
2009	VICI Prize, Nederlandse Organisatie voor Wetenschappelijk Onderzoek
2009	AHA Special Recognition-Award and Galenus-von-Pergamon-Award
2008	Paul-Martini-Award and ESC Outstanding Achievement-Award
2008	W.H. Hauss-Preis 2008, German Society of Atherosclerosis Research
2005	Forßmann-Award, University of Bochum
2004	Arthur-Weber-Award, German Cardiac Society
2003	Basic Science-Award, GlaxoSmithKline-Foundation

## OTHER ACTIVITIES

### Editor

2018	Guest Editor, <i>Circulation</i>
2014 - 2017	Consulting Editor, <i>Circulation Research</i>
2013	Regional Editor Europe, <i>Molecular Metabolism</i>
2012	Senior Associate Editor, <i>Arteriosclerosis, Thrombosis &amp; Vascular Biology</i>
2010	Editor-in-Chief, <i>Thrombosis &amp; Haemostasis</i>

### Editorial Boards

- *Basic Research in Cardiology*
- *Cardiovascular Research*
- *Circulation Research*
- *EMBO Molecular Medicine*
- *European Heart Journal*

### Reviewer (selection)

- *Blood, Circulation, EMBO Journal, Immunity*
- *Journal of Clinical Investigation, Journal of Experimental Medicine*
- *Journal of the American College of Cardiology, Lancet*
- *Nature, Nature Medicine, PNAS, Science (Signaling, Transl Med)*

### Reviewer (organisations)

- European Research Council (ERC), Consolidator Grant Panelist
- German Research Foundation (DFG), Suisse National Fund (SNF)
- MPG Minerva Foundation, Wellcome Trust, British Heart Foundation
- The Nobel Komitee, Karolinska Institutet, Stockholm, Sweden

### Scientific Advisory Boards

- Helmholtz Society, Health
- Paris Cardiovascular Research Center (PARCC)
- Dept. Cardiology, Universität Zürich (evaluation committee)
- *Carolus Therapeutics Inc.* (Chair SAB 2008-2016)
- *ProterixBio Inc.* (2014-2016)

### Patents granted

- US 10/411,397 (JAM-1 small molecule antagonists & antibodies)
- DE 10328277.7 (customized parallel wall flow chamber)
- WO 2007/042263 A1 (peptide antagonist CKEY2)
- US 65/701,601 (MIF receptor antagonists)
- WO 2009/015884 A1 (GAG-antagonising MCP-1 mutants)
- EP 12181862.9 – 1211 (Inhibitors of CD40-TRAF6 interaction)
- US 9,750,717 B2 (Inhibitors of CD40-TRAF6 interaction)

### Founder

- *Carolus Therapeutics Inc.*
- *Cartesio Therapeutics Inc.*

### THIRD PARTY FUNDING (selection)

2019 - 2023	DZHK – BHF grant (with J. Erdmann) <i>Molecular genetics</i> , budget: 0.4 M€
2019 - 2025	DFG Excellence Cluster SyNergy; PI funding, budget: 0.7 M€
2018 - 2022	DFG SFB1123 projects A1 (with Y. Döring), A10 (with J. Duchene), and Z3 <i>Chemokine receptors in atherosclerosis</i> , budget: 2.65 M€
2017 - 2019	DZHK HRHV grant (with E. Lutgens), <i>TRAF-STOPs</i> , budget: 0.6 M€
2017 - 2019	NIH grant 5R01HL122843-03 (with D. Saleheen), <i>CXCL12</i> , budget: 0.2 M€
2016 - 2021	ERC Advanced Grant °692511 <i>PROVASC</i> , budget: 2.5 M€
2016 - 2019	DFG SFB914 project B08 (with O. Söhnlein), <i>Alarmins in leukocyte recruitment</i> , budget: 0.45 M€
2014 - 2018	DFG SFB1123 projects A1 (with Y. Döring), B4 (with A. Schober), and Z3, <i>Chemokines and miRs in atherosclerosis</i> , budget: 2.2 M€
2011 - 2020	BMBF project MHA VD1.2 <i>Vascular Immunotherapy</i> , budget: 1.45 M€
2011 - 2016	NWO project VICI 918.10.616, <i>Chemokine interactome</i> , budget: 1.5 M€
2011 - 2016	Leducq Transatlantic Network of Excellence <i>CVGeneF(x)</i> , budget: 0.7 M€
2012 - 2015	BMBF grants TUR10/I13 & META JTC2011 <i>Metabolic stress</i> , budget: 0.4 M€
2012 - 2015	DFG SFB1054 project B04, <i>DC and Treg interactions</i> , budget: 0.45 M€
2012 - 2015	DFG SFB914 project B08 (with O. Söhnlein), <i>Differential recruitment of monocyte subsets</i> , budget: 0.4 M€
2011 - 2014	DFG program project FOR809, <i>Chemokines &amp; adhesion molecules in cardiovascular pathogenesis</i> (P1-4/6/12, WE1913/10&12), budget: 3.5 M€
2010 - 2016	ERC Advanced Grant °249929 <i>Atheroprotect</i> , budget: 2.5 M€
2009 - 2013	DFG International Research Training Group GRK1508 <i>Euregio Cardiovascular Research School</i> , budget: 2.6 M€
2009 - 2011	DFG TR57 project P7 (with H. Wasmuth), <i>MIF and CXCR2</i> , budget: 0.1 M€
2008 - 2011	DFG SFB542 project A07 (with J. Bernhagen), A12 (with P. Mertens), <i>MIF receptor complexes, YB-1 &amp; RANTES</i> , WE1913/13, budget: 1.0 M€
2007 - 2010	DFG program project FOR809, <i>Chemokines &amp; adhesion molecules in cardiovascular pathogenesis</i> (P1-4/6, WE1913/10&12), budget: 2.5 M€
2006 - 2008	DFG project WE 1913/9, <i>JAM-A in atherosclerosis</i> , budget: 0.4 M€
2005 - 2008	DFG SFB542 project C12 (with P. Mertens), <i>YB-1 &amp; RANTES expression</i> , budget: 0.25 M€
2004 - 2007	DFG project WE 1913/7-1&2 (with A. Schober), <i>SDF-1<math>\alpha</math> and vascular progenitor cells</i> , budget: 0.2 M€
2003 - 2006	DFG project BE 1977/2-1 (with J. Bernhagen), <i>MIF in inflammatory processes and atherogenesis</i> , budget: 0.1 M€
2003 - 2006	DFG project WE 1913/5-1, <i>Function of platelet chemokines</i> , budget: 0.25 M€
2001 - 2004	DFG project WE 1913/2-3, <i>Integrins and chemokines in atherogenic recruitment</i> , budget: 0.25 M€
1997 - 2001	Junior Research Group in Biosciences WE 1913/2-1&2 <i>Integrins &amp; chemokine receptors: mechanisms and pathophysiology</i> , budget: 0.6 Mio. €

## MENTORING (selection)

### PhD students

cand. rer. nat. Maria Aslani (LMU München, current)  
Dr. rer. nat. Carlos Neideck ('summa cum laude', 2018, LMU München)  
Dr. rer. nat. Manuela Mandl ('magna cum laude', 2017, LMU München)  
Dr. rer. nat. Martin Schmitt ('summa cum laude', 2014, RWTH Aachen)  
Elena Vasina, PhD (2013, Maastricht University)  
Dr. rer. nat. Sarawuth Wantha ('magna cum laude', 2013, RWTH Aachen)  
Dr. rer. nat. Sakine Simsekyilmaz ('magna cum laude', 2012, RWTH Aachen)  
Dr. rer. nat. Maik Drechsler ('magna cum laude', 2011, RWTH Aachen)  
Dr. rer. nat. Yvonne Döring ('summa cum laude', 2011, RWTH Aachen)  
Dr. rer. nat. Alisina Sarabi ('magna cum laude', 2011, RWTH Aachen)  
Dr. rer. nat. Svenja Meiler ('summa cum laude', 2010, RWTH Aachen)  
Dr. rer. nat. Regina Krohn ('summa cum laude', 2008, RWTH Aachen)  
Dr. rer. medic. Elisa Liehn, MSc ('summa cum laude', 2008, RWTH Aachen)  
Dr. rer. nat. Line Fraemohs ('summa cum laude', 2007, RWTH Aachen)  
Dr. rer. nat. Georg Ostermann ('summa cum laude', 2002, LMU München)  
Dr. rer. hum. biol. Wolfgang Erl ('summa cum laude', 1996, LMU München)

### MD students

cand. med. Julian Leberzammer (LMU München, current)  
cand. med. Veit Eckart (LMU München, current)  
Dr. med. Sebastian Mause ('summa cum laude', 2011, RWTH Aachen)  
Dr. med. Denis Gümbel ('summa cum laude', 2010, RWTH Aachen)  
Dr. med. Yassin Djalali-Talab ('summa cum laude', 2009, RWTH Aachen)  
Dr. med. Dipl.-Chem. Thomas Baltus ('summa cum laude', 2008 RWTH)  
Dr. med. Ute Zeiffer ('summa cum laude', 2008 RWTH Aachen)  
Dr. med. Britta Butzbach ('magna cum laude', 2006, RWTH Aachen)  
Dr. med. Alma Zerneck ('summa cum laude', 2004, LMU München)  
Dr. med. Tobias Weber ('summa cum laude', 2004, LMU München)  
Dr. med. Philipp von Hundelshausen ('summa cum laude', 2003, LMU)  
Dr. med. Celina Wardemann ('magna cum laude', 1998, LMU München)

### Postdocs

Dr. rer. nat. Kiril Bidzhekov	Dr. rer. nat. Jiri Neuzil
Dr. rer. nat. Xavier Blanchet	Dr. rer. nat. Heidi Noels
Dr. rer. nat. Yvonne Döring	Dr. rer. nat. Otilia Postea
Dr. rer. nat. Johan Duchene	Dr. med. Zuzanna Rowinska
Dr. Virginia Egea	Dr. med. Donato Santovito
Dr. med. Chimge Günther	Dr. Emiel van der Vorst, PhD
Dr. Remco Megens, PhD	Dr. med. Felix Vogt

### Habilitations

PD Dr. med. Philipp von Hundelshausen  
PD Dr. med. Michael Hristov  
PD Dr. ing. Rory Koenen  
PD Dr. med. Elisa Liehn  
PD Dr. med. Andreas Schober  
PD Dr. med. Oliver Soehnlein, PhD  
PD Dr. med. Alma Zerneck

### Professors

Prof. Dr. Oliver Söhnlein, (W3, Münster)  
Prof. Dr. Yvonne Döring (W2, Bern)  
Prof. Dr. Norbert Gerdes (W2, Düsseldorf)  
Prof. Dr. Esther Lutgens (AMC Amsterdam)  
Prof. Dr. Andreas Schober (W2, LMU Munich)  
Prof. Dr. Oliver Söhnlein (W2, LMU Munich)  
Prof. Dr. Alma Zerneck (W3, Würzburg)

## BIBLIOGRAPHY (ORCID 0000-0003-4610-8714)

### 10 most important original articles (citations: *Scopus/GoogleScholar*)

1. Duchene J, Novitzky-Basso I, Casanova-Acebes M, Bianchini M, Etheridge SL, Hub E, Nitz K, Thiriot A, Ullmar MH, Bacon A, Bidzhekov K, Ruelicke T, Caamano J, Moss PAH, Megens R, von Andrian UH, Hidalgo A, **Weber C\***, Rot A\*. Atypical chemokine receptor 1 regulates haematopoiesis. *Nat Immunol* 2017; 18:753-761. \*corresponding authors (27/33 citations).
2. von Hundelshausen P, Agten S, Eckardt V, Schmitt MMW, Blanchet X, Ippel H, Neideck C, Bidzhekov K, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen J, Li H, Leberzammer J, Naumann R, Dijkgraf I, Nicolaes G, Döring Y, Soehnlein O, Lutgens E, Heemskerk J, Koenen R, Mayo K, Hackeng T, **Weber C**. Structure-function mapping of the chemokine interactome enables tailored intervention in acute and chronic inflammation. *Sci Transl Med* 2017;9 (384): eaah6650 (36/47 citations).
3. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RTA, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, **Weber C**. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. *Nat Med* 2014;20:368-376 (285/365 citations).
4. Zerneck A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Nazari-Jahantigh M, Lutgens E, Wang S, Olson E, Schober A, **Weber C**. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal* 2009;2:ra81 (842/1144 citations).
5. Koenen RR, von Hundelshausen P, Nesmelova IV, Zerneck A, Liehn EA, Sarabi A, Kramp BK, Piccinini A, Kowalska A, Kungl AJ, Hackeng TM, Mayo KH, **Weber C**. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. *Nat Med* 2009;15:97-103 (282/375 citations).
6. Zerneck A, Bot I, Djalali Talab Y, Shagdarsuren E, Meiler S, Liehn EA, Schober A, Soehnlein O, Sperandio M, Tacke F, Biessen EA, **Weber C**. Protective role of Cxcr4/Cxcl12 unveils the importance of neutrophils in atherosclerosis. *Circ Res* 2008;102:209-217 (288/413 citations).
7. Bernhagen J, Krohn R, Lue H, Gregory JL, Zerneck A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, **Weber C**. MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. *Nat Med* 2007;13:587-596 (730/1013 citations).
8. Huo YQ, Schober A, Forlow SB, Smith D, Hyman M, Jung S, Littman DR, **Weber C**, Ley K. Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. *Nat Med* 2003;9:61-67 (757/1048 citations).
9. Ostermann G, Weber KSC, Zerneck A, Schröder A, **Weber C**. JAM-1 is a ligand for the  $\beta$ 2 integrin LFA-1 involved in transendothelial migration of leukocytes. *Nat Immunol* 2002;3:151-158 (462/637 citations).
10. von Hundelshausen P, Weber KSC, Huo YQ, Proudfoot A, Nelson PJ, Ley K, **Weber C**. Deposition of RANTES by platelets triggers monocyte recruitment on inflamed and atherosclerotic endothelium. *Circulation* 2001; 103:1772-1777 (438/607 citations).

### Bibliometric parameters (as per Dec 31, 2020)

Cumulative Impact factor (IF, 621 original and review articles):	4718.7
Cumulative IF (384 original articles):	3068.3
Cumulative IF (118 original articles as first/last author):	1041.8
Cumulative IF (237 review articles and commentaries):	1650.4
Average IF of Original articles (first/last author):	8.8
Total citations since 1996 ( <i>Scopus</i> )	39,881
Total citations ( <i>Clarivate/GoogleScholar</i> )	38,971 / 58,573
Citations p.a. between 2016 and 2020 ( <i>Scopus/GoogleScholar</i> )	2835-3535 / 4207-5479
<i>h</i> -index/ <i>m</i> -index <i>Scopus</i>	105 / 3.6
<i>h</i> -index <i>Publons/Clarivate</i>	103
<i>h</i> -index <i>GoogleScholar</i>	126
<i>c</i> -index (PLoS Biol 2019;10.1371/without self-citations)	4.29/4.23 (rank #2903/3373)

## Publications in *Nature*, *Science* and *Cell / Immunity*-Families (n=38)

1. Rot A et al. & **Weber C**, Duchene J (2020) Myeloid cells do not express atypical chemokine receptor 1. *Cell Stem Cell*, in revision.
2. Kontos C, El et al. & **Weber C**, Kapurniotu A, Bernhagen J (2020) An engineered soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. *Nat. Commun.* 11:5981.
3. Bartelt A, Weber C (2020) Mitochondrial ejection for cardiac protection: the macrophage connection. *Cell Metabol.* 32:512-513.
4. Santovito D\*, Egea V\*, Bidzhekov K\*, Natarelli L\*, Mourão A et al. & Sattler M, **Weber C** (2020) Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. *Sci. Transl. Med.* 12:eaaz2994. \*equal contribution.
5. Adrover JM et al. & **Weber C**, Lizasoain I, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A (2020) Pro-programmed “disarming” of the neutrophil proteome reduces the magnitude of inflammation. *Nat. Immunol.* 21:135-144.
6. Bianchini M, Duchêne J\* et al. & **Weber C\***, Megens RTA (2019) PD-L1 on non-classical monocytes reveals their origin and immuno-regulatory function. *Sci. Immunol.* 4:eaar3054. \*corresponding author.
7. Silvestre-Roig C, Braster Q et al. & **Weber C**, Hidalgo A, Wong G, Nicolaes G, Soehnlein O (2019) Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. *Nature* 569:236-240.
8. Yin C, Ackermann S et al., **Weber C\***, Zipfel PF\*, Skerka C\*, Habenicht AJR\* (2019) ApoE attenuates unresolvable inflammation by complex formation with activated C1q. *Nat. Med.* 25:496-506. \*equal contribution.
9. Adrover J et al. & **Weber C**, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A (2019) A neutrophil clock coordinates immune defense and vascular protection. *Immunity* 50:390-402.
10. Braza MS et al. & **Weber C**, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WMJ, Ochando J (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. *Immunity* 49:819-828.
11. Winter C et al. & **Weber C**, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O (2018) Chronopharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. *Cell Metab.* 28:175-182.
12. Soehnlein O, Steffens S, Hidalgo A, **Weber C** (2017) Neutrophils in immunity and immunopathology – protagonists and targets of chronic inflammation. *Nat. Rev. Immunol.* 17:248-261.
13. Krishnasamy K et al. & **Weber C**, Adams RH, Limbourg FP (2017) Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. *Nat. Commun.* 8:952.
14. Duchene J et al. & **Weber C\***, Rot A\* (2017) Atypical chemokine receptor 1 on nucleated erythroid cells regulates haematopoiesis. *Nat. Immunol.* 18:753-761. \*corresponding authors.
15. von Hundelshausen P et al. & **Weber C** (2017) Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. *Sci. Transl. Med.* 9:eaah6650.
16. Gamrekashvili J et al. & **Weber C**, Limbourg FP (2016) Regulation of monocyte cell fate by blood vessels. *Nat. Commun.* 7:12597.
17. Hartmann P et al. & **Weber C**, Schober A (2016) Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. *Nat. Commun.* 7:10521.
18. Finan B et al. & **Weber C**, Rozman J, Fuchs S, Gailus-Durner V, Hrabě de Angelis M, Hoffman SM, Gelfanov V, Yang B, Tschöp MH, DiMarchi R, Müller TD (2016) Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. *Cell* 167:843-857.
19. Schober A, Nazari-Jahantigh M, **Weber C** (2015) Mechanisms of microRNAs in atherosclerosis. *Nat. Rev. Cardiol.* 12:361-374.
20. Alard JE et al. & **Weber C**, Soehnlein O (2015) Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. *Sci. Transl. Med.* 7:317ra196.

21. Hu D et al. & **Weber C**, Lehmann T, Beer M, Grabner R, Maffia P, Weih F, Habenicht AJR (2015) ATLOs control aortic immunity and protect against atherosclerosis via VSMC-LT $\beta$  receptors. *Immunity* 42:1100-15. (IF 24.082)
22. Hinkel R et al. & **Weber C**, Bock-Marquette I, Olson EN, Posern G, Deindl E, Niemann H, Kupatt C (2014) MRTF-A mediates vessel growth and maturation via CCN1 and CCN2. *Nat. Commun.* 5:3970.
23. Schober A et al. & **Weber C** (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. *Nat. Med.* 20:368-376.
24. Casanova-Acebes M et al. & **Weber C**, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. *Cell* 153:1025–1035.
25. **Weber C**, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. *Nat. Med.* 17:1410-1422
26. Zhou Z et al. & **Weber C**, Schober A (2011) Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis through the release of CXCL1 from endothelium. *Cell Metab.* 13:592-600.
27. Soehnlein O et al. & **Weber C** (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. *Sci. Transl. Med.* 3:103ra98.
28. **Weber C** (2010) Far from the heart: receptor cross-talk in remote conditioning. *Nat. Med.* 16:760-762.
29. Goossens P et al. & **Weber C**, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. *Cell Metab.* 12:142-153.
30. Koenen RR, **Weber C** (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. *Nat. Rev. Drug Discov.* 9:141-53.
31. Zernecke A et al. & **Weber C** (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci. Signal.* 2:ra81.
32. Koenen RR et al. & **Weber C** (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. *Nat. Med.* 15:97-103.
33. Choi EY et al. & **Weber C**, Chavakis T (2008) Del-1 is an endogenous inhibitor of leukocyte-endothelial adhesion preventing inflammatory cell recruitment. *Science* 322:1101-4.
34. **Weber C**, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis. *Nat. Rev. Immunol.* 8:802-815.
35. Bernhagen J et al. & **Weber C** (2007) MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. *Nat. Med.* 13:587-596.
36. **Weber C**, Fraemohs L, Dejana E (2007) The role of junctional adhesion molecules in vascular inflammation. *Nat. Rev. Immunol.* 7:467-477.
37. Huo YQ, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, **Weber C**, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. *Nat. Med.* 9:61-67.
38. Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C** (2002) JAM-1 is a ligand for the  $\beta$ 2 integrin LFA-1 involved in transendothelial migration of leukocytes. *Nat. Immunol.* 3:151-158.



## Original articles (selection, IF year of publication, \* Clarivate top 1% in subject area)

1. Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Guangyao Y, Wang S, Brandhofer M, Bou-rilhon P, Megens RTA, Hoffmann A, Asare Y, Gao Y, Leng L, Mägdefessel L, Eckstein HH, Pelisek J, Gokce O, Bucala R, Dichgans M, **Weber C**, Kapurniotu A, Bernhagen J (2020) An engineered soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. *Nat. Commun.* 11:5981. (IF 12.353)
2. Shami A, Atzler D, Bosmans L, Winkels H, Meiler S, Lacy M, van Tiel C, Megens R, Nitz K, Baardman J, Buerger C, Janjic A, Riccardi C, Edsfeldt A, Monaco C, Daemen M, de Winther M, Nilsson J, **Weber C**, Gerdes N, Gonçalves I, Lutgens E (2020) Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. *Eur. Heart J.* 41:2938-2948. (IF 22.673)
3. Santovito D\*, Egea V\*, Bidzhekov K\*, Natarelli L\*, Mourão A, Wichapong K, Blanchet B, Aslani M, Horckmans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C** (2019) Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy. *Sci. Transl. Med.*, 12:eaaz2994. \*equal contribution. (IF 16.304)
4. Döring Y, Cimen I, Jansen Y, Aslani M, Gencer S, Peters LJF, Duchene J, **Weber C\***, van der Vorst EPC\* (2020) B-cell specific CXCR4 protects against atherosclerosis development and increases plasma IgM levels. *Circ. Res.* 126:787-788. (IF 14.467) \*equal contribution.
5. Eckardt V, Miller MC, Blanchet X, Leberzammer J, Duchene J, Söhnlein O, Megens RTA, Ludwig AK, Dregni A, Faussner A, Wichapong K, Ippel H, Dijkgraaf I, Hackeng TM, **Weber C**, Gabius HJ, Mayo KH, von Hundelshausen P (2020) Chemokines and galectins form heterodimers to modulate inflammation. *EMBO Reports* 21:e47852. (IF 7.497)
6. Adrover JM, Aroca-Crevillén A, Crainiciuc G, Ostos F, Rojas-Vega Y, Rubio-Ponce A, Cilloniz C, Bonzón-Kulichenko E, Calvo E, Rico D, Moro MA, **Weber C**, Lizasoain I, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A (2020) Programmed “disarming” of the neutrophil proteome reduces the magnitude of inflammation. *Nat. Immunol.* 21:135-144. (IF 21.809)
7. Bianchini M, Duchêne J\*, Santovito D, Schloss MJ, Evrard M, Winkels H, Aslani M, Mohanta SK, Horckmans M, Blanchet X, Lacy M, von Hundelshausen P, Atzler D, Habenicht A, Gerdes N, Pelisek J, Ng LG, Steffens S, **Weber C\***, Megens RTA (2019) PD-L1 on non-classical monocytes reveals their origin and immunoregulatory function.. *Sci. Immunol.* 4:eaar3054. \*corresponding author.
8. \* Silvestre-Roig C, Braster Q, Wichapong K, Ernest Y, Lee E, Teulon JM, Berrebeh N, Winter J, Adrover JM, Santos GS, Froese A, Lemnitzer P, Ortega-Gómez A, Chevre R, Marschner J, Schmuski A, Winter C, Perez-Olivares, Chang P, Paulin N, Schoufour T, Hartwig H, González Ramos S, Kamp F, Megens RTA, Mowen KA, Gunzer M, Maegdefessel L, Hackeng T, Lutgens E, Daemen M, von Blume J, Anders HJ, Nikolaev V, Pellequer JL, **Weber C**, Hidalgo A, Wong G, Nicolaes G, Soehnlein O (2019) Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. *Nature* 569:236-240. (IF 41.577)
9. \* Yin C\*, Ackermann S\*, Mohanta SK, Ma Z, Nietzsche S, Westermann M, Peng L, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Eckstein HH, Pelisek J, Herms J, Röber S, Arzberger T, Habenicht L, Binder C, **Weber C\***, Zipfel PF\*, Skerka C\*, Habenicht AJR\* (2019) ApoE attenuates unresolvable inflammation by complex formation with activated C1q. *Nat. Med.* 25:496-506. \*equal contribution. (IF 32.621)
10. \* Döring Y, van der Vorst EPC, Duchene J, Jansen Y, Gencer S, Bidzhekov K, Atzler D, Santovito D, Rader DJ, Saleheen D, **Weber C** (2019) CXCL12 derived from endothelial cells promotes atherosclerosis to drive coronary artery disease. *Circulation* 139:1338-1340 (IF 18.881)
11. \* Cremer S, Michalik K, Pfisterer L, Winter C, Boon R, Fischer A, Jaé N, Muhly-Reinholz M, John D, Uchida S, **Weber C**, Poller W, Günther S, Braun T, Li Y, Maegdefessel L, Perisic Matic L, Hedin U, Soehnlein O, Zeiher A, Dimmeler S (2019) Hematopoietic deficiency of the long non-coding RNA MALAT1 promotes atherosclerosis and plaque inflammation. *Circulation* 139:1320-1334. (IF 18.881)
12. \* Adrover JM, Del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga-Encabo H, Silvestre-Roig C, Rossaint J, Cossío I, Lechuga-Vieco AV, García-Prieto J, Gómez-Parrizas M, Quintana JA,

- Ballesteros I, Martin-Salamanca S, Aroca-Crevillen A, Chong SZ, Evrard M, Balabanian K, López J, Bidzhekov K, Bachelerie F, Abad-Santos F, Muñoz-Calleja C, Zarbock A, Soehnlein O, **Weber C**, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A. (2019) A neutrophil timer coordinates immune defense and vascular protection. *Immunity* 50:390-402. (IF 19.734)
13. Seijkens TTP, Poels K, Meiler S, van Tiel CM, Kusters PJH, Reiche M, Atzler D, Winkels H, Tjwa M, Poelman H, Slütter B, Kuiper J, Gijbels M, Kuivenhoven JA, Perisic Matic L, Paulsson-Berne G, Hedin U, Hansson GK, Nicolaes GA, Daemen MAJP, **Weber C**, Gerdes N, de Winther M, Lutgens E (2019) Deficiency of the T cell regulator CBL-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death. *Eur. Heart J.* 40:372-382. (IF 23.425)
  14. Baaten CCF, Meacham S, de Witt SM, Feijge MAH, Adams DJ, Akkerman JW, Cosemans JM, Jupe S, Kostadima M, Mattheij NJA, Prins MH, Ramirez-Solis R, Soehnlein O, **Weber C**, White JK, Ouwehand WH, Heemskerk JWM (2018) A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding. *Blood* 132:e35-e46. (IF 15.132)
  15. Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJ, Pérez-Medina C, Conde P, Garcia M, Gonzalez-Perez M, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress R, Salem F, Rialdi A, Reiner T, Boros P, Strijkers G, Calcagno C, Ginhoux F, Marazzi I, Lutgens E, Nicolaes G, **Weber C**, Swirski F, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea M, Mulder WM, Ochando J (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. *Immunity* 49:819-828. (IF 19.734)
  16. \* Casanova-Acebes M, Nicolás-Ávila JA, Weiss LA, Adrover JM, A-González N, Devi S, Mortha A, Quintana J, Crainiciuc J, Leiva MN, **Weber C**, Nagasawa T, Soehnlein O, Merad M, Ng L, Hidalgo A (2018) Neutrophils instruct homeostatic and pathological states in naive tissues. *J. Exp. Med.* 215:2778-95. (IF 10.790)
  17. Paulin N, Viola JR, Maas SL, de Jong R, Fernandes-Alnemri T, **Weber C**, Drechsler M, Döring Y, Soehnlein O (2018) Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. *Circulation* 138:321-323. (IF 18.881)
  18. Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelmann H, Schumski A, Winter J, Drechsler M, de Jong R, Immler R, Sperandio M, Hristov M, Zeller T, Nicolaes GAF, **Weber C**, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O (2018) Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. *Cell Metab.* 28:175-182. (IF 20.565)
  19. Busygina K, Jamasbi J, Seiler T, Deckmyn H, **Weber C**, Brandl R, Lorenz R, Siess W (2018) Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation. *Blood*, 131:2605-2616. (IF 15.132)
  20. Horckmans M, Bianchini M, Santovito D, Megens R, Springael JY, Vacca M, Di Eusanio M, Moschetta A, **Weber C**, Duchene J, Steffens S (2018) Pericardial adipose tissue regulates granulopoiesis, fibrosis and cardiac function after myocardial infarction. *Circulation* 137:948-960. (IF 18.881)
  21. Seijkens TTP, van Tiel CM, Atzler D, Kusters PJ, Zarzycka B, Lameijer M, Soehnlein O, Hoeksema M, Gijbels MJ, Beckers L, den Toom M, Schrijver R, Boon L, Fay F, Jongejan A, Moerland PD, Vriend G, Bleij-levens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MP, Nicolaes GA, Mulder WJ, **Weber C**, Lutgens E (2018) Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. *J. Am. Coll. Cardiol.* 71:527-542. (IF 16.834)
  22. Winkels H, Meiler S, Smeets E, Lievens D, Engel D, Spitz C, Bürger C, Beckers L, Dandl A, Reim S, Ahmadsei M, Hartwig H, Holdt L, Hristov M, Megens RTA, Schmitt MM, Biessen EA, Borst J, Faussner A, **Weber C**, Lutgens E, Gerdes N (2017) CD27 co-stimulation increases frequency of regulatory T cells and reduces atherosclerosis in hyperlipidemic mice. *Eur. Heart J.* 38:3590-3599. (IF 23.425)
  23. Krishnasamy K, Limbourg A, Kapanadze T, Gamrekelashvili J, Beger C, Häger C, Falk C, Napp LC, Bauersachs J, Mack M, Haller H, **Weber C**, Adams RH, Limbourg FP (2017) Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. *Nat. Commun.* 8:952. (IF 12.353)
  24. Döring Y, Noels H, van der Vorst EPC, Egea V, Drechsler M, Mandl M, Neideck C, Pawig L, Jansen J, Schröder K, Bidzhekov K, Megens R, Theelen W, Klinkhammer BM, Boor P, Schurgers L, van Gorp R, Ries C, Kusters PJH, van der Wal A, Hackeng T, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D, Teupser D,

- Holdt LM, Rader DJ, Saleheen D, **Weber C** (2017) Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity. *Circulation* 136:388-403. (IF 18.881)
25. Rinne P, Rami M, Nuutinen S, Lyytikäinen LP, Raitoharju E, Oksala N, Ring L, Cai M, Hraby VJ, Lehtimäki T, **Weber C**, Steffens S (2017) Melanocortin 1 receptor signaling regulates cholesterol transport in macrophages. *Circulation* 136:83-97. (IF 18.881)
26. Duchene J, Novitzky-Basso I, Casanova-Acebes M, Bianchini M, Etheridge SL, Hub E, Nitz K, Thiriot A, Ulvmar MH, Bacon A, Bidzhekov K, Ruelicke T, Caamano J, Moss PAH, Megens R, von Andrian UH, Hidalgo A, **Weber C**, Rot A\* (2017) Atypical chemokine receptor 1 on nucleated erythroid cells regulates haematopoiesis. *Nat. Immunol.* 18:753-761. \*corresponding authors. (IF 21.809)
27. von Hundelshausen P, Agten S, Eckardt V, Schmitt MMW, Blanchet X, Ippel H, Neideck C, Bidzhekov K, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen J, Li H, Leberzammer J, Naumann R, Dijkgraf I, Nicolaes G, Döring Y, Soehnlein O, Lutgens E, Heemskerk J, Koenen R, Mayo K, Hackeng T, **Weber C** (2017) Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. *Sci. Transl. Med.* 9:eaah6650. (IF 16.710)
28. Asare Y, Azombo FA, Schmitz C, Lue H, Tilstam PV, Gessner A, Lange D, **Weber C**, Dichgans M, Jan-kowski J, Pardi R, de Winther MPJ, Noels H, Bernhagen J (2017) Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. *Proc. Natl. Acad. Sci. USA.* 114:E2766-E2775. (IF 9.504)
29. Tufanli O, Telkoparan P, Acosta-Alvear D, Hamid SM, Onat UI, Kocaturk B, Cimen I, Walter P, **Weber C**, Erbay E (2017) Targeting IRE1 with small molecules counteracts progression of atherosclerosis. *Proc. Natl. Acad. Sci. USA.* (IF 9.504)
30. \* Horckmans M, Ring L, Duchene J, Santovito D, Schloss M, Drechsler M, **Weber C**, Soehnlein O, Steffens S (2017) Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. *Eur. Heart J.* 38:187-197. (IF 23.425)
31. Agten SM, Koenen RR, Ippel H, Eckardt V, von Hundelshausen P, Mayo KH, **Weber C**, Hackeng TM (2016) Probing functional heteromeric chemokine protein-protein interactions through conformation-assisted oxime-linkage. *Angew. Chem. Int. Ed. Engl.* 55:14963-14966. (IF 11.994)
32. Chong SZ, Evrard M, Devi S, Chen J, Lim Y, See P, Zhang Y, Adrover J, Lee B, Tan L, Li J, Liong K, Phua C, Balachander A, Boey A, Liebl D, Tan S, Chan J, Balabanian K, Harris JE, Bianchini M, Duchene J, **Weber C**, Lum J, Poidinger M, Renia L, Wang C, Larbi A, Randolph GJ, Weninger W, Looney M, Krummel M, Biswas S, Ginhoux F, Hidalgo A, Bachelier F, Ng LG (2016) CXCR4 identifies transitional bone marrow pre-monocytes that replenish the mature monocyte pool for peripheral responses. *J. Exp. Med.* 213:2293-2314. (IF 11.991)
33. Finan B, Clemmensen C, Zhu Z, Vanacker K, Müller L, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Flamant D, Biebermann H, Döring Y, **Weber C**, Rozman J, Fuchs S, Gailus-Durner V, Hrabě de Angelis M, Hoffman SM, Gelfanov V, Yang B, Tschöp MH, DiMarchi R, Müller TD (2016) Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. *Cell* 167:843-857. (IF 30.410)
34. Ortega-Gomez A, Salvermoser M, Rossaint J, Pick R, Brauner J, Lemnitzer P, Tilgner J, de Jong R, Megens R, Jamasbi J, Döring Y, Pham C, Scheiermann C, Siess W, Drechsler M, **Weber C**, Grommes J, Zarbock A, Walzog B, Soehnlein O (2016) Cathepsin G controls arterial but not venular myeloid cell recruitment. *Circulation* 134:1176-1188. (IF 19.309)
35. Viola, JR, Lemnitzer P, Jansen Y, Winter C, Neideck C, Silvestre-Roig C, Döring Y, Drechsler M, **Weber C**, Cenac N, Soehnlein O (2016) Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogresion in mice. *Circ. Res.* 119:1030-1038. (IF 13.965)
36. Gamrekelashvili J, Giagnorio R, Jussofie J, Soehnlein O, Duchene J, Briseño CG, Ramasamy SK, Krishnasamy K, Limbourg A, Kapanadze T, Ishifune C, Hinkel R, Radtke F, Strobl LJ, Zimmer-Strobl U, Napp LC, Bauersachs J, Haller H, Yasutomo K, Kupatt C, Murphy KM, Adams RH, **Weber C**, Limbourg FP (2016) Regulation of monocyte cell fate by blood vessels. *Nat. Commun.* 7:12597. (IF 12.124)
37. Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, Miller J, **Weber C**, Ley K (2016) CCR5+T-bet+FoxP3+ effector CD4 T cells drive atherosclerosis. *Circ. Res.* 118:1540-52. (IF 13.965)

38. Hartmann P, Zhou Z, Natarelli L, Nazari-Jahantigh M, Wei Y, Zhu M, Grommes J, Steffens S, **Weber C**, Schober A (2016) Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. *Nat. Commun.* 7:10521. (IF 12.124)
39. Alard JE, Ortega-Gomez A, Wichapong K, Bongiovani D, Horckmanns M, Megens RTA, Leoni G, Ferraro B, Rossaint J, Paulin N, Hinkel R, Blanchet X, Gaillard F D'Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, Steffens S, Kupatt C, Nicolaes GAF, **Weber C**, Soehnlein O (2015) Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. *Sci. Transl. Med.* 7:317ra196. (IF 16.264)
40. \* Soehnlein O, Ortega-Gómez A, Döring Y, **Weber C** (2015) Neutrophil-macrophage interplay in atherosclerosis: protease-mediated cytokine processing versus NET release. *Thromb. Haemost.* 114:866-7. (IF 5.255)
41. Medina I, Cougole C, Drechsler M, Bermudez B, Koenen RR, Wolfs I, Doering Y, Herias V, Gijbels M, Bot I, de Jager S, Moscai A, **Weber C**, Cleutjens J, van Berkel TJC, Maridonneau-Parini I, Soehnlein O, Biessen EAL (2015) Hck/Fgr kinase deficiency reduces plaque growth and stability by blunting monocyte recruitment and intraplaque motility. *Circulation* 132:490-501. (IF 17.202)
42. Hu D, Mohanta SK, Peng L, Yin C, Srikakulapu P, Grassia G, MacRitchie N, Dever G, Gordon P, Burton FL, Ialenti A, Sabir SR, McInnes IB, Brewer JM, Garside P, **Weber C**, Lehmann T, Beer M, Grabner R, Maffia P, Weih F, Habenicht AJR (2015) ATLOs control aortic immunity and protect against atherosclerosis via VSMC-LT $\beta$  receptors. *Immunity* 42:1100-15. (IF 24.082)
43. Jamasbi, J, Megens R, Münch G, Ungerer M, Faussner A, Lorenz R, Sherman S, Walker A, Gojal P, **Weber C**, Brandl R, Jung S, Farndale R, Elia N, Siess W (2015) Inhibition of platelet activation in blood exposed to atherosclerotic plaques by GPVI-Fc and anti-GPVI antibodies: functional and imaging studies. *J. Am. Coll. Cardiol.* 65:2404-15. (IF 17.759)
44. Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM, Grommes J, Hinkel R, Kupatt C, **Weber C**, Döring Y, Zarbock A, Soehnlein O (2015) Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. *Circ. Res.* 116:827-35. (IF 11.551)
45. Karshovska E, Zhao Z, Blanchet X, Schmitt M, Bidzhekov K, Soehnlein O, von Hundelshausen P, Mattheij NJA, Cosemans JM, Megens RTA, Koepfel TA, Schober A, Hackeng TM, **Weber C**, Koenen RR (2015) Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice. *Circ. Res.* 116:587-99. (IF 11.551)
46. Hinkel R, Trenkwalder T, Petersen B, Stachel G, Lee, S, Husada W, Gesenhues F, Hannappel E, DiMaio JM, Hatzopoulos AK, Theisen D, Boekstegers P, LeNoble F, Nordheim A, Reichart B, **Weber C**, Bock-Marquette I, Olson EN, Posern G, Deindl E, Niemann H, Kupatt C (2014) MRTF-A mediates vessel growth and maturation via CCN1 and CCN2. *Nat. Commun.* 5:3970. (IF 11.470)
47. Noels H, Zhou B, Tilstam P, Theelen W, Li X, Akhtar S, Simsekylmaz S, Liehn E, Schober A, Adams R, Bernhagen J, Döring Y, **Weber C** (2014) Deficiency of endothelial Cxcr4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in mice. *Arterioscler. Thromb. Vasc. Biol.* 34:1209-20. (IF 6.008)
48. Rossaint J, Herter J, van Aken H, Napirei M, Döring Y, **Weber C**, Soehnlein O, Zarbock A (2014) Synchronized integrin and chemokine activation is crucial in neutrophil extracellular trap-mediated acute lung injury. *Blood* 123:2573-84. (IF 10.452)
49. \* Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RTA, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, **Weber C** (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. *Nat. Med.* 20:368-376. (comment in *Sci. Transl. Med.* 6:230ec57; *Arterioscler. Thromb. Vasc. Biol.* 2014;34:e15-6; recommended in F1000 prime) (IF 28.223, 285/365 citations)
50. Li X, Penfold M, Megens R, Koenen RR, Thiemann A, Heyll K, Akhtar S, van Zandvoort M, Schall TJ, **Weber C\***, Schober A\* (2014) Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. *Circulation* 129:1244-53. \*corresponding authors. (IF 15.073)
51. Döring Y, Noels H, Mandl M, Kramp B, Lievens D, Drechsler M, Megens R, Tilstam PV, Langer M, Hartwig H, Sperandio M, Soehnlein O, **Weber C** (2014) Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest. *Circ. Res.* 114:976-981. (comment in *Circ. Res.* 114:935-937) (IF 11.019)

52. \* Hartwig H, Drechsler M, Lievens D, Kramp B, von Hundelshausen P, Lutgens E, **Weber C**, Döring Y, Soehnlein O (2014) Platelet-derived PF4 reduces neutrophil apoptosis in inflammation. *Thromb. Haemost.* 111:562-4. (IF 4.984)
53. Chèvre R, González-Granado JM, Megens RT, Sreeramkumar V, Silvestre-Roig C, Molina-Sanchez P, **Weber C**, Soehnlein O, Hidalgo A, Andrés V (2014) High-resolution imaging of intravascular atherogenic inflammation in live mice. *Circ. Res.* 114:770-9. (IF 11.019)
54. Schmitt MMN, Megens RTA, Zerneck A, Bidzhekov K, van den Akker NM, Rademakers T, van Zandvoort MA, Hackeng TM, Koenen RR, **Weber C** (2014) Endothelial JAM-A guides monocytes into flow-dependent predilection sites of atherosclerosis. *Circulation* 129:66-76. (IF 15.073)
55. Lievens D, Habets KL, Robertson AK, Laouar Y, Winkels H, Rademakers T, Beckers L, Wijnands E, Boon L, Mosaheb M, Ait-Oufella H, Mallat Z, Flavell RA, Rudling M, Binder C, Gerdes N, Biessen EAL, **Weber C**, Daemen MJAP, Kuiper J, Lutgens E (2013) Abrogated transforming growth factor- $\beta$  receptor II (TGF $\beta$ RII) signaling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. *Eur. Heart J.* 34:3717-27. (comment in *Eur. Heart J.* 34:3684) (IF 14.723)
56. Liehn E, Kanzler I, Kunschalla S, Kroh A, Simsekylmaz S, Sönmez T, Bucala R, Bernhagen J, **Weber C** (2013) Compartmentalized protective versus detrimental effects of endogenous MIF mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. *Arterioscler. Thromb. Vasc. Biol.* 33:2180-86 (IF 5.533)
57. \* Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chèvre R, A-González N, Kunisaki Y, Zhang D, van Rooijen N, Silberstein L, **Weber C**, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. *Cell* 153:1025–1035. (IF 33.116)
58. Wei Y, Nazari-Jahantigh M, Heyll K, Thiemann A, Chan L, **Weber C**, Schober A (2013) The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. *Circulation* 127:1609-1619. (IF 14.948)
59. Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, Kemmerich K, Ortega-Gómez A, Mandl M, Vijayan S, Projahn D, Garlachs CD, Koenen RR, Hristov M, Lutgens E, Zerneck A, **Weber C** (2013) Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. *EMBO Mol. Med.* 5:471-481. (IF 8.245)
60. Wantha S, Alard JE, Megens RTA, van der Does A, Döring Y, Drechsler M, Pham CT, Wang MW, Wang JM, Gallo RL, von Hundelshausen P, Lindbom L, Hackeng T, **Weber C**, Soehnlein O (2013) Neutrophil-derived cathelicidin promotes adhesion of classical monocytes, *Circ. Res.* 112:792-801. (IF 11.089)
61. \* Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhe Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, **Weber C**, Schober A (2012) MicroRNA-155 promotes atherosclerosis by derepressing Bcl6 in macrophages. *J. Clin. Invest.* 122:4190-4202. (IF 12.812, 282/381 citations)
62. Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, Theelen W, Kramp BK, Butoi E, Soehnlein O, Heemskerk JWM, Ludwig A, **Weber C\***, Koenen RR\* (2012) Role of platelet CX3CR1 in monocyte recruitment to arterial lesions. *Arterioscler. Thromb. Vasc. Biol.* 32:1186-1193. \*equal contribution. (IF 6.338)
63. Döring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S, Gallo R, **Weber C**, Soehnlein O (2012) Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. *Circ. Res.* 110:1052-6. (IF 11.861)
64. Döring Y, Manthey H, Drechsler M, Lievens D, Manca M, Hartwig H, Busch M, Koenen RR, Soehnlein O, Zenke M, Daemen M, Lutgens E, **Weber C**, Zerneck A (2012) Autoantigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. *Circulation* 125:1673-83. (IF 15.202)
65. Grommes J, Alard JE, Drechsler M, Wantha S, Mörgelin M, Kuebler W, Jacobs M, von Hundelshausen P, Markart P, Preissner KT, Hackeng TM, Koenen RR, **Weber C**, Soehnlein O (2012) Disruption of platelet-derived chemokine heteromers abolishes endotoxin-induced lung injury. *Am. J. Resp. Crit. Care Med.* 185:628-36. (IF 11.041)
66. Liehn E, Tuchscheerer N, Kanzler I, Drechsler M, Fraemohs L, Schuh A, Koenen R, Zandler S, Soehnlein O, Hristov M, Grigorescu G, Urs A, Leabu M, Bucur I, Merx M, Zerneck A, Bernhagen J, Schober A, **Weber C**

- (2011) Double-edged role of the CXCL12-CXCR4 axis in experimental myocardial infarction. *J. Am. Coll. Cardiol.* 58:2415-23. (comment in *J. Am. Coll. Cardiol.* 58:2424-2426) (IF 14.156)
67. Soehnlein O, Wantha S, Simsekylmaz S, Doering Y, Megens RT, Mause SF, Drechsler M, Smeets R, Weinandy S, Schreiber F, Gries T, Vijayan S, van Zandvoort M, Agerberth B, Pham CT, Gallo RL, Hackeng TM, Liehn EA, Hristov M, Zerneck A, Klee D, **Weber C** (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. *Sci. Transl. Med.* 3:103ra98. (comment in *Nat. Rev. Drug Discov.* 2011;11:902; *SciBX* 2011;1227) (IF 7.804)
68. **Weber C**, Meiler S, Döring Y, Koch M, Drechsler M, Megens R, Rowinska Z, Bidzhekov K, Fecher C, Ribechini E, van Zandvoort M, Binder C, Jelinek Y, Hristov M, Boon L, Jung S, Korn T, Lutz MB, Förster I, Zenke M, Hieronymus T, Junt T, Zerneck A (2011) CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T-cell homeostasis in mice. *J. Clin. Invest.* 121:2898–2910. (IF 13.069)
69. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Reinholz M, van Zandvoort M, **Weber C**, Schober A (2011) Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis through the release of CXCL1 from endothelium. *Cell Metab.* 13:592-600. (IF 13.668)
70. Schober A, Hristov M, Forbrig R, Kofler S, Löhr B, Schumann U, Krötz F, Leibig M, König A, Kazcmerek I, Reichart B, Klauss V, **Weber C**, Sohn HY (2011) CD34<sup>+</sup>CD140b<sup>+</sup> cells and CXCL12 predict the severity of cardiac allograft vasculopathy. *Eur. Heart J.* 32:476-84. (IF 10.478)
71. de Jager SC, Bermúdez B, Bot I, Koenen RR, Bot M, Kavelaars A, de Waard V, Heijnen CJ, Muriana FJ, **Weber C**, van Berkel TJ, Kuiper J, Lee SJ, Abia R, Biessen EA (2011) Growth differentiation factor-15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. *J. Exp. Med.* 208:217-25. (IF 13.853)
72. Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen RR, Xu H, Schilling AB, **Weber C**, Ye RD, Dinner AR, Tang WJ (2010) Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin degrading enzyme. *EMBO J.* 29:3952-3966. (IF 10.124)
73. Liehn EA, Piccinini A, Koenen RR, Soehnlein O, Adage T, Fatu R, Curaj A, Popescu A, Zerneck A, Kungl A, **Weber C** (2010) A potent CCL2 antagonist suitable for combined treatment of vascular and ischemia-reperfusion injury. *J. Am. Coll. Cardiol.* 56:1847-57. (IF 14.293)
74. Lievens D, Zerneck A, Seijkens T, Beckers L, Munnix ICA, Wijnands E, Flavell RA, Noelle RJ, Biessen EA, Daemen MJAP, Heemskerk JWM, **Weber C**, Lutgens E (2010) Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. *Blood* 116:4317-27. (IF 10.558)
75. \* Drechsler M, Megens R, van Zandvoort M, **Weber C**, Soehnlein O (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis in mice. *Circulation* 122:1837-45. (IF 14.432, 349/511 citations)
76. Berres ML, Rueland A, Koenen RR, Moreno Zaldivar M, Schmitz P, Streetz KL, Gassler N, Weiskirchen R, **Weber C**, Trautwein C, Wasmuth HE (2010) Antagonism of the chemokine CCL5 (RANTES) ameliorates experimental liver fibrosis *in vivo*. *J. Clin. Invest.* 120:4129-40. (IF 14.152)
77. Shagdarsuren E, Bidzhekov K, Mause S, Simsekylmaz S, Polakowski T, Hawlisch H, Gessner JE, Zerneck A, **Weber C** (2010) C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. *Circulation* 122:1026-1036. (IF 14.432)
78. Goossens P, Gijbels MJJ, Zerneck A, van der Made I, Beckers L, Buurman WA, Daemen MJ, Kalinke U, **Weber C**, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. *Cell Metab.* 12:142-153. (IF 18.207)
79. Mause SF, Ritzel E, Liehn EA, Hristov M, Bidzhekov K, Mueller-Newen G, Soehnlein O, **Weber C** (2010) Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. *Circulation* 122:495-506. (IF 14.432)
80. Subramanian P, Karshovska E, Reinhard P, Zhou Z, Megens RTA, Akhtar S, Li X, van Zandvoort M, Ludin C, **Weber C**, Schober A (2010) Lysophosphatidic acid receptors LPA<sub>1</sub> and LPA<sub>3</sub> promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. *Circ. Res.* 107:96-105. (IF 9.504)
81. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zerneck A, de Winther M, Engel S, Seijkens T, Boon L, Ahonen C, Noelle R, Daemen M, Biessen EA, **Weber C** (2010) Deficient CD40-TRAF6 signaling in

- leukocytes prevents atherosclerosis and skews the immune response towards an anti-inflammatory profile. **J. Exp. Med.** 207:391-404. (IF 14.776)
82. Hristov M, Gumbel D, Shagdarsuren E, Lutgens E, Zerneck A, **Weber C** (2010) Soluble CD40 ligand impairs peripheral blood angiogenic outgrowth cell function and increases neointima formation after arterial injury. **Circulation** 121:315-324. (comment in *Circulation* 121:197-199) (IF 14.432)
  83. \* Zerneck A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Nazari Jahantigh M, Lutgens E, Wang S, Olson EN, Schober A, **Weber C** (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. **Sci. Signal.** 2:ra81. (comment in *Science* 326:1590) (IF 6.354, 842/1144 citations)
  84. \* Karlmark KR, Weiskirchen R, Henning W, Zimmermann HW, Gassler N, Ginhoux F, **Weber C**, Merad M, Luedde T Trautwein C, Tacke F (2009) Hepatic recruitment of the inflammatory Gr1<sup>+</sup> monocyte subset upon liver injury promotes hepatic fibrosis. **Hepatology** 50:261-274. (IF 10.840)
  85. Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zerneck A, Schwarz N, Reiss K, Lindbom L, **Weber C**, Ludwig A (2009) Regulated release and functional modulation of junctional adhesion molecule-A by disintegrin metalloproteinases. **Blood** 113:4799-809. (IF 10.555)
  86. Matthijsen RA, de Winther MP, **Weber C**, Herias V, Gijbels MJ, Buurman WA (2009) Macrophage specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. **Circulation** 119:2188-95. (IF 14.816)
  87. \* Landsman L\*, Ber-On L\*, Zerneck A\*, Kim K, Krautgamer R, Shagdarsuren E, Lira SA, Weisman IL, **Weber C**, Jung S (2009) CX3CR1-mediated cell survival in monocyte homeostasis and atherogenesis. **Blood** 113:963-972. (comment in *Blood* 113:767-768) \*equal contribution. (IF 10.555, 271/367 citations)
  88. \* Koenen RR, von Hundelshausen P, Nesmelova IV, Zerneck A, Liehn EA, Sarabi A, Kramp B, Piccinini A, Kowalska A, Kungl AJ, Hackeng TM, Mayo KH, **Weber C** (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. **Nat. Med.** 15:97-103. (IF 27.136, 282/375 citations)
  89. Choi EY, Chavakis E, Czabanka MA, Langer H, Fraemohs L, Economopoulou M, Orlandi A, Kundu RK, Zheng YY, Ballantyne CM, Constant SL, Aird W, Papayannopoulou T, Gahmberg C, Udey MC, Vajkoczy P, Quertermous T, Dimmeler S, **Weber C**, Chavakis T (2008) Del-1 is an endogenous inhibitor of leukocyte-endothelial adhesion preventing inflammatory cell recruitment. **Science** 322:1101-4. (comment in *Nat. Rev. Immunol.* 9:6-7) (IF 28.103)
  90. **Weber C**, Kraemer S, Drechsler M, Lue H, Koenen R, Kapurniotu A, Zerneck A, Bernhagen J (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. **Proc. Natl. Acad. Sci. USA.** 105:16278-16283. (IF 9.380)
  91. Soehnlein O, Zerneck A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, **Weber C**, Lindbom L (2008) Neutrophil secretion products pave the way for inflammatory monocytes. **Blood** 112:1461-71. (IF 10.432)
  92. Vogt F, Zerneck A, Beckner M, Krott N, Bosserhoff AK, Hoffmann R, Jahnke T, Kelm M, **Weber C**, Blindt R (2008) Blocking of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation after vascular injury in hyperlipidemic apolipoprotein E knock-out mice. **J. Am. Coll. Cardiol.** 52:302-11. (comment in *J. Am. Coll. Cardiol.* 52:312-314) (IF 11.438)
  93. Frommhold D, Ludwig A, Bixel G, Zarbock A, Babushkina I, Lange-Sperandio B, Ellies LG, Marth JD, Beck-Sickinge AG, Linderkamp O, Zerneck A, **Weber C**, Vestweber D, Ley K, Sperandio M (2008) Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. **J. Exp. Med.** 205:1435-46. (IF 15.463)
  94. \* Zerneck A, Bot I, Djalali-Talab Y, Shagdarsuren E, Meiler S, Liehn EA, Schober A, Soehnlein O, Sperandio M, Tacke F, Biessen EA, **Weber C** (2008) Protective role of Cxcr4/Cxcl12 unveils the importance of neutrophils in atherosclerosis. **Circ. Res.** 102:209-217. (comment in *Circ. Res.* 102:154-156) (IF 9.721, 288/413 citations)

95. Shagdarsuren E, Bidzhekov K, Liehn EA, Djalali-Talab Y, Hristov M, Matthijsen RA, Buurman WA, Zerneck A, **Weber C** (2008) C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. *Circulation* 117:70-78. (IF 12.755)
96. Krohn R, Raffetseder U, Bot I, Zerneck A, Shagdarsuren E, Liehn EA, van Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, **Weber C** (2007) YB-1 controls CCL5 expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. *Circulation* 116:1812-20. (IF 12.755)
97. Galkina E, Harry B, Ludwig A, Liehn E, Sanders J, Bruce A, **Weber C**, Ley K (2007) CXCR6 promotes atherosclerosis by supporting T cell homing, interferon- $\gamma$  production and macrophage accumulation in the aortic wall. *Circulation* 116:1801-1811. (IF 12.755)
98. Bot I, de Jager SCA, Zerneck A, **Weber C**, van Berkel TJ, Biessen EA (2007) Perivascular mast cell activation aggravates atherogenesis and contributes to plaque destabilization in ApoE<sup>-/-</sup> mice. *Circulation* 115:2516-2525. (comment in *Circulation* 115:2471) (IF 12.755)
99. \* Bernhagen J, Krohn R, Lue H, Gregory J, Zerneck A, Koenen R, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, **Weber C** (2007) MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. *Nat. Med.* 13:587-596. (comment in *Nat. Rev. Drug Dis.* 6:435) (IF 26.382, 730/1013 citations)
100. Hristov M, Zerneck A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, **Weber C** (2007) Importance of CXCR2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. *Circ. Res.* 100:590-597. (IF 9.721)
101. Braunersreuther V, Zerneck A, Steffens S, Burger F, Pelli G, Luckow B, Mach F, **Weber C** (2007) CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. *Arterioscler. Thromb. Vasc. Biol.* 27:373-9. (IF 7.221, 204/279 citations)
102. Lucerna M, Zerneck A, de Nooijer R, de Jager S, Bot I, van der Lans C, Kholova I, van Berkel TJC, Ylä-Herttua S, **Weber C**, Biessen EAL (2007) Vascular endothelial growth factor induces plaque expansion in ApoE knockout mice by promoting *de novo* leukocyte recruitment. *Blood* 109:122-129. (comment in *Blood* 109:2-3) (IF 10.896)
103. Zerneck A\*, Liehn EA\*, Gao JL, Murphy PM, Kuziel WA, **Weber C** (2006) Deficiency in CCR5 but not in CCR1 protects from neointima formation in atherosclerosis-prone mice: involvement of IL-10. *Blood*. 107:4240-4243. \* equal contribution. (IF 10.370)
104. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, Seitz B, Kapurniotu A, Kwok C, Dewor M, Bosserhoff AK, Bernhagen J, Hanrath P, Hoffmann R, **Weber C** (2006) A novel drug-eluting stent coated with an integrin-binding cRGD peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. *J. Am. Coll. Cardiol.* 47:1786-1795. (IF 9.701)
105. Zerneck A, Bidzhekov K, Özüyan B, Liehn EA, Fraemohs L, Firzlaff-Lüscher J, Lüscher B, Schrader J, **Weber C** (2006) CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. *Circulation* 113:2120-27 (IF 10.940)
106. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, **Weber C** (2005) Statin treatment after onset of sepsis in a murine model improves survival, *Circulation* 112:117-124. (IF 11.632)
107. Mause SF, von Hundelshausen P, Zerneck A, Koenen R, **Weber C** (2005) Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on inflamed and atherosclerotic endothelium. *Arterioscler. Thromb. Vasc. Biol.* 25:1512-18. (IF 7.053, 243/326 citations)
108. Zerneck A, Schober A, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, **Weber C** (2005) SDF-1 $\alpha$ /CXCR4 axis is instrumental for neointimal hyperplasia and recruitment of smooth muscle cell progenitors. *Circ. Res.* 96:784-791. (IF 9.408, 291/399 citations)
109. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Proudfoot AEI, Adriaens W, Hackeng TM, **Weber C** (2005) Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. *Blood* 105:924-930. (IF 10.131, 238/310 citations)



110. Schober A, Zernecke A, Liehn E, von Hundelshausen P, Knarren S, Kuziel WA, **Weber C** (2004) The crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in atherosclerosis-prone mice involves early monocyte recruitment and CCL2 presentation on platelets. **Circ. Res.** 95:1125-1133. (IF 9.972)
111. Merx MW, Lin EA, Janssens U, Lütticken R, Schrader J, Hanrath P, **Weber C** (2004) HMG-CoA-reductase inhibitor simvastatin profoundly improves survival in sepsis. **Circulation** 109:2560-2565. (IF 12.563, 217/294 citations)
112. Zeiffer U, Schober A, Lietz M, Liehn EA, Erl W, Emans N, Yan ZQ, **Weber C** (2004) Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. **Circ. Res.** 94:776-784. (comment in *Circ. Res.* 94:706) (IF 9.972)
113. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, **Weber C** (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. **Circulation** 109:380-5. (IF 12.563)
114. Schober A, Knarren S, Lin E, Lietz M, Guttenbach M, **Weber C** (2003) Crucial role of stromal cell-derived factor-1 $\alpha$  in neointima formation after arterial injury in apolipoprotein E-deficient mice. **Circulation** 108:2491-2497. (IF 11.164)
115. Baltus T, Weber KSC, Johnson Z, Proudfoot AEI, **Weber C** (2003) Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes. **Blood** 102:1085-88. (IF 10.120)
116. \* Huo YQ, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, **Weber C**, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. **Nat. Med.** 9:61-67. (IF 30.550, 757/1048 citations)
117. Schober A, Manka D, von Hundelshausen P, Huo YQ, Hanrath P, Sarembock IJ, Ley K, **Weber C** (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. **Circulation** 106:1523-1529 (comment in *Circulation* 106:1433). (IF 10.255, 287/383 citations)
118. \* Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C** (2002) JAM-1 is a ligand for the  $\beta$ 2 integrin LFA-1 involved in transendothelial migration of leukocytes. **Nat. Immunol.** 3:151-158 (comment in *Nat. Immunol.* 3:116). (IF 27.868, 475/637 citations)
119. Huo YQ, **Weber C**, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K (2001) The chemokine KC but not MCP-1 triggers arrest of monocytes in carotid arteries with early atherosclerotic lesions. **J. Clin. Invest.** 108:1307-14 (see also *J. Clin. Invest.* 108:1269). (IF 14.118, 228/319 citations)
120. Weber KSC, Ostermann G, Zernecke A, Schröder A, Klickstein LB, **Weber C** (2001) Dual role of H-ras in regulation of LFA-1 activity by SDF-1 $\alpha$ : implications for leukocyte transmigration. **Mol. Biol. Cell** 12:3074-3086. (IF 7.700)
121. von Hundelshausen P, Weber KSC, Huo YQ, Proudfoot A, Nelson PJ, Ley K, **Weber C** (2001) Deposition of RANTES by platelets triggers monocyte recruitment on inflamed and atherosclerotic endothelium. **Circulation** 103:1772-1777 (comment in *Circulation* 103:1718). (IF 10.517, 438/607 citations)
122. **Weber C**, Weber KSC, Klier C, Gu H, Horuk R, Wank R, Nelson PJ (2001) Specialized roles of the chemokine receptors CCR1 and CCR5 in recruitment of monocytes and Th1-like/CD45RO<sup>+</sup> T cells. **Blood** 97:1144-1146 (comment in *Blood* 97:833). (IF 9.273)
123. **Weber C**, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, Frankenberger M, Weber KSC, Ziegler-Heitbrock HWL (2000) Differential chemokine receptor expression and function in human monocyte subpopulations. **J. Leukoc. Biol.** 67:699-704. (IF 4.342, 260/406 citations)
124. Weber KSC, Nelson PJ, Gröne HJ, **Weber C** (1999) Expression of CCR2 by endothelial cells: implications for MCP-1-mediated wound injury repair and in vivo inflammatory activation of endothelium. **Arterioscler. Thromb. Vasc. Biol.** 19:2085-2093. (IF 5.406, 220/291 citations)
125. Weber KSC, Draude G, Erl W, de Martin R, **Weber C** (1999) Monocyte arrest and transmigration on inflamed endothelium in shear flow is inhibited by adenoviral gene transfer of I $\kappa$ B- $\alpha$ . **Blood** 93:3685-3693. (IF 8.782)

126. Weber KSC, Klickstein LB, **Weber C** (1999) Specific activation of the  $\beta$ 2 integrins Mac-1 and LFA-1 by chemokines in mononuclear cells mediated by distinct activation pathways via the  $\alpha$  subunit cytoplasmic domains. *Mol. Biol. Cell.* 10:861-873. (IF 7.527)
127. Erl W, Hansson GK, de Martin R, Draude G, Weber KSC, **Weber C** (1999) Nuclear factor- $\kappa$ B regulates apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. *Circ. Res.* 84:668-677. (IF 8.281)
128. Piali L, **Weber C**, La Rosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B (1998) The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. *Eur. J. Immunol.* 28:961-972. (IF 5.438, 193/249 citations)
129. **Weber C**, Erl W, Weber KSC, Weber PC (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from hypercholesterolemic patients. *J. Am. Coll. Cardiol.* 30:1212-1217 (comment in *J. Am. Coll. Cardiol.* 30:1218). (IF 6.704, 379/504 citations)
130. **Weber C**, Springer TA (1997) Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to  $\alpha$ IIb $\beta$ 3 and stimulated by platelet activating factor. *J. Clin. Invest.* 100:2085-2093. (IF 9.667, 285/363 citations)
131. **Weber C**, Kitayama J, Springer TA (1996) Differential regulation of  $\beta$ 1 and  $\beta$ 2 integrin avidity by chemo-attractants in eosinophils. *Proc. Natl. Acad. Sci. USA.* 93: 10939-944. (IF 9.040)
132. **Weber C**, Alon R, Moser B, Springer TA (1996) Sequential regulation of  $\alpha$ 4 $\beta$ 1 and  $\alpha$ 5 $\beta$ 1 integrin avidity by CC chemokines in monocytes: Implications for transendothelial chemotaxis. *J. Cell Biol.* 134:1063-1073. (IF 12.005, 198/257 citations)
133. **Weber C**, Erl W, Weber K, Weber PC (1996) Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. *Circulation* 93:1488-492. (IF 9.762)
134. **Weber C**, Erl W, Pietsch A, Weber PC (1995) Aspirin inhibits NF- $\kappa$ B mobilization and monocyte adhesion in stimulated human endothelial cells. *Circulation.* 91:1914-1917. (IF 9.762, 243/317 citations)
135. **Weber C**, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HWL, Weber PC (1994) Antioxidants inhibit monocyte adhesion by suppressing nuclear factor- $\kappa$ B mobilization and induction of vascular cell adhesion molecule 1 in endothelial cells stimulated to generate radicals. *Arterioscler. Thromb. Vasc. Biol.* 14:1665-1673. (IF 5.317, 305/377 citations)

## Review articles (selection, \* top 1% in subject area)

1. Bartelt A, **Weber C** (2020) Mitochondrial ejection for cardiac protection: the macrophage connection. *Cell Metabol.* 32:512-513. (IF 21.567)
2. Lacy M, Gencer S, Atzler D, van der Vorst E, Döring Y, **Weber C** (2020) Immuno-inflammatory, thrombo-haemostatic, and cardiovascular mechanisms in COVID-19. *Thromb. Haemost.* 120:1629-1641. (IF 4.379)
3. Santovito D\*, Egea V\*, Bidzhekov K\*, Ntarelli L\*, Mourão A, Wichapong K, Blanchet B, Aslani M, Horckmans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C** (2020) Autophagy unleashes non-canonical miRNA functions. *Autophagy* 16:2294-2296. (IF 9.770)
4. Döring Y, Noels H, van der Vorst E, **Weber C** (2020) Seeing is repairing – how imaging-based timely interference with CXCR4 could improve repair after myocardial infarction. *Eur. Heart J.* ehaa625. (IF 22.673)
5. Evans PC, Rainger GE, Mason JC, Guzik TJ, Stamataki Z, Hoefler I, Waltenberger J, **Weber C**, Bochaton-Piallat ML, Bäck M (2020) Endothelial dysfunction in COVID-19. *Cardiovasc. Res.* cvaa230. (IF 8.168)
6. Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik T, Hoefler I, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, **Weber C**, Wilkinson F, Bochaton-Piallat ML, Evans PC (2020) Endothelial function in cardiovascular precision medicine: a position paper on behalf of the European Society of Cardiology. *Cardiovasc. Res.* cvaa085. (IF 8.168)
7. Bartelt A, Leipsic J, **Weber C** (2019) The new age of radiomic risk profiling: perivascular fat at the heart of the matter. *Eur. Heart J.* 40:3544-3546. (IF 22.673)
8. Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, **Weber C** (2019) Immunotherapy for cardiovascular disease. *Eur. Heart J.* 40:3937-3946. (IF 22.673)
9. Lacy M, Atzler D, de Winther M, **Weber C**, Lutgens E (2019) Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. *Pharmacol. Ther.* 193:50-62. (IF 10.557)
10. Ketelhuth DFJ, Lutgens E, Bäck M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefler I, Libby P, O'Neill L, **Weber C**, Evans P (2019) Immunometabolism and atherosclerosis: perspectives and clinical significance – A position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. *Cardiovasc. Res.* 115:1385-1392. (IF 7.014)
11. Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen M, Egido J, Evans PC, Francis SE, Ketelhuth D, Lutgens E, Matter C, Monaco C, Steffens C, Stroes E, Vindis C, **Weber C**, Hoefler IE on behalf of the ESC Working Group on Atherosclerosis and Vascular Biology (2019) Identifying the anti-inflammatory response to lipid lowering therapy. *Cardiovasc. Res.* 115:10-19. (IF 7.014)
12. Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, Leistner DM, Jakob P, Nakagawa S, Blankenberg S, Engelhardt S, Thum T, **Weber C**, Meder B, Hajjar R, Landmesser U (2018) Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. *Eur. Heart J.* 39:2704-2716. (IF 23.425)
13. van der Vorst EPC, **Weber C** (2018) Metabolomic profiling of atherosclerotic plaques: towards improved cardiovascular risk stratification. *Eur. Heart J.* 39:2311-2313. (IF 23.425)
- 14.\* **Weber C**, von Hundelshausen P (2017) CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting. *Circ. Res.* 121:1119-1121. (IF 15.211)
15. Soehnlein O, Steffens S, Hidalgo A, **Weber C** (2017) Neutrophils as protagonists and targets in chronic inflammation. *Nat. Rev. Immunol.* 17:248-261. (IF 41.982)
16. Döring Y, Soehnlein O, **Weber C** (2017) Neutrophil extracellular traps in atherosclerosis and atherothrombosis. *Circ. Res.* 120:736-743. (IF 15.211)
17. **Weber C**, Shantsila E, Hristov M, Caligiuri G, Guzik T, Heine GH, Hoefler I, Monaco C, Peter K, Rainger E, Siegbahn A, Steffens S, Woyta J, Ziegler-Heitbrock L, Lip GYHL (2016) Role and analysis of monocyte subsets in cardiovascular disease: joint position paper of the ESC WG on Atherosclerosis & Vascular Biology and the ESC WG on Thrombosis. *Thromb. Haemost.* 116:626-37. (IF 5.627)

18. Schober A, **Weber C** (2016) Mechanisms of microRNAs in atherosclerosis. *Ann. Rev. Pathol.* 11:583-616. (IF 26.853)
19. Hoefler IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM, Caligiuri G, Dimmeler S, Egido J, Evans PC, Guzik T, Kwak BR, Landmesser U, Mayr M, Monaco C, Pasterkamp G, Tuñón J, **Weber C** (2015) Novel methodologies for biomarker discovery in atherosclerosis. *Eur. Heart J.* 36:2635-42. (IF 15.064)
20. Bäck M, **Weber C**, Lutgens E (2015) Regulation of atherosclerotic plaque inflammation. *J. Intern. Med.* 278:462-82. (IF 7.803)
21. Hartmann P, Schober A, **Weber C** (2015) Chemokines and miRNAs in atherosclerosis. *Cell. Mol. Life Sci.* 72:3253-66. (IF 5.694)
22. Megens R, Bianchini M, Schmitt M, **Weber C** (2015) Optical imaging innovations for atherosclerosis research: multiphoton microscopy and optical nanoscopy. *Arterioscler. Thromb. Vasc. Biol.* 35:1339-46. (IF 5.969)
23. Schober A, Nazari-Jahantigh M, **Weber C** (2015) Mechanisms of microRNAs in atherosclerosis. *Nat. Rev. Cardiol.* 12:361-374. (IF 10.533)
24. Santovito D, Egea V, **Weber C** (2015) DNA methylation and epigenetics: exploring the terra incognita of the atherosclerotic landscape. *Eur. Heart J.* 36:956-8. (IF 15.064)
25. Kwak B, Bäck M, Bochaton-Piallat ML, Caligiuri G, Daemen MAJ, Davies P, Hoefler I, Holvoet P, Krams R, Monaco C, Steffens S, Virmani R, **Weber C**, Wentzel J, Evans PC (2014) Biomechanical factors in atherosclerosis: mechanisms and clinical implications. *Eur. Heart J.* 35:3013-3020. (IF 15.203)
26. Mohanta SK, Yin C, Peng L, Srikakulapu P, Bontha V, Hu D, Weih F, **Weber C**, Gerdes N, Habenicht AJR (2014) Artery tertiary lymphoid organs control innate and adaptive immune responses in advanced mouse atherosclerosis during aging. *Circ. Res.* 114:1772-1787. (IF 11.019)
27. Silvestre-Roig C, de Winther MPJ, **Weber C**, Daemen MJ, Lutgens E, Soehnlein O (2014) Atherosclerotic plaque destabilization: mechanisms, models and therapeutic strategies. *Circ. Res.* 114:214-26. (IF 11.019)
28. Ylä-Herttuala S, Bentzon J, Daemen M, Falk E, Garcia H, Herrmann J, Hoefler I, Jukema J, Krams R, Kwak B, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys P, Waltenberger J, **Weber C**, Tokgözoğlu L (2013) Stabilising atherosclerotic plaques: an update. *Eur. Heart J.* 34:3251-8. (IF 14.723)
29. Koenen RR, **Weber C** (2011) Chemokines: new targets in atherosclerosis. *EMBO Mol. Med.* 3:713-25. (IF 7.795)
- 30.\* **Weber C**, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. *Nat. Med.* 17:1410-1422. (IF 22.462, 1030/1551 citations)
- 31.\* Mause SF, **Weber C** (2010) Microparticles - protagonists of a novel communication network for intercellular information exchange. *Circ. Res.* 107:1047-57. (IF 9.504, 519/733 citations)
32. **Weber C** (2010) Far from the heart: receptor cross-talk in remote conditioning. *Nat. Med.* 16:760-2. (IF 25.430)
33. Koenen RR, **Weber C** (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. *Nat. Rev. Drug Discov.* 9:141-53. (IF 28.712)
34. Soehnlein O, Lindbom L, **Weber C** (2009) Neutrophils and the control of monocyte extravasation. *Blood* 114:4613-23. (IF 10.555)
35. Zernecke A, Shagdarsuren E, **Weber C** (2008) Chemokines in atherosclerosis: an update. *Arterioscler. Thromb. Vasc. Biol.* 28:1897-1908. (IF 6.858, 264/541 citations)
36. **Weber C**, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis. *Nat. Rev. Immunol.* 8:802-815. (IF 30.006, 574/815 citations)
37. Zernecke A, Bernhagen J, **Weber C** (2008) Macrophage migration inhibitory factor in cardiovascular disease. *Circulation* 117:1594-1602. (IF 14.595)

38. Merx MW, **Weber C** (2007) Sepsis and the heart. *Circulation* 116:782-792. (IF 12.755)
39. **Weber C**, Fraemohs L, Dejana E (2007) The role of junctional adhesion molecules in vascular inflammation. *Nat. Rev. Immunol.* 7:467-477. (IF 28.300, 333/478 citations)
40. von Hundelshausen P, **Weber C** (2007) Platelets as immune cells: bridging inflammation and vascular disease. *Circ. Res.* 100:27-40. (IF 9.721, 475/666 citations)
41. **Weber C**, Koenen R (2006) Fine-tuning leukocyte responses: towards a chemokine interactome. *Trends Immunol.* 27:268-73. (IF 10.213)
42. Merx M, **Weber C** (2006) Statins: a preventive strike against infection-related mortality in patients with cardiovascular disease? *Lancet* 367:372-373. (IF 25.800)
43. **Weber C** (2005) Platelets and chemokines in atherosclerosis: partners in crime. *Circ. Res.* 96:612-616. (IF 9.408)
- 44.\* Zernecke A, **Weber C** (2005) Inflammatory mediators of atherosclerotic vascular disease. *Basic Res. Cardiol.* 100:93-101. (IF 2.806)
45. Hristov M, **Weber C** (2004) Endothelial progenitor cells: pathophysiological aspects and possible clinical relevance. *J. Cell. Mol. Med.* 8:498-508. (IF 2.153, 375/541 citations)
46. **Weber C**, Zernecke A, Schober A (2004) Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. *Arterioscler. Thromb. Vasc. Biol.* 24:1997-2008. (IF 7.432)

## Invited key note and plenary lectures (selection)

1. **Weber C** (2020) Non-canonical effects of endothelial microRNAs of atherosclerosis. International Vascular Biology Meeting (IVBM) 2020, Seoul, South Korea.
2. **Weber C** (2019) Novel strategies for immunotherapy of atherosclerosis. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
3. **Weber C** (2018) Inflammation: a treatment target in CAD prevention. ESC, Munich, Germany.
4. **Weber C** (2017) Targeting chemokines to control plaque cell infiltration. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
5. **Weber C** (2017) Regulation of atherosclerosis by microRNAs. European Atherosclerosis Society (EAS) Congress 2017, Prag, Czech Republic.
6. **Weber C** (2016) Chemokine interactome mapping for tailored intervention in acute and chronic inflammation. Gordon Research Conference on *Chemotactic Cytokines*, Girona, Spain
7. **Weber C** (2015) Chemokines in atherosclerosis. GTH Congress 2015, Düsseldorf, Germany.
8. **Weber C** (2015) Regulation of microRNA trafficking in atherosclerosis. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
9. **Weber C** (2014) miRNAs and regional susceptibility to atherosclerosis. FCVB 2014, Barcelona, Spain.
10. **Weber C** (2014) Chemokines and miRNAs and atherosclerosis. IVBM 2014, Kyoto, Japan
11. **Weber C** (2013) MicroRNAs and atherosclerosis: from molecular mechanism to potential clinical applications. President's Lecture, Italian Society of Atherosclerosis, Roma, Italy.
12. **Weber C** (2013) Targeting platelets in vascular inflammation. European Society of Cardiology (ESC), Amsterdam, Netherlands
13. **Weber C** (2013) Dendritic and regulatory T-cells in atherosclerosis. American Diabetes Association Congress 2013, Chicago, USA.
14. **Weber C** (2013) Emerging mechanisms of chemokine receptor control of atherosclerosis. The Ottawa Research Conference, Ottawa, Canada.
15. **Weber C** (2012) CXCL12 - is it important? AHA Scientific Sessions, Los Angeles, USA.
16. **Weber C** (2012) Therapeutic targeting of microRNAs in atherosclerosis. ESC, Munich, Germany.
17. **Weber C** (2012) Role of chemokines in cardiovascular disease. Gordon Research Conference on *Chemotactic Cytokines*, Il Ciocco, Italy.
18. **Weber C** (2012) Chemokines as therapeutic targets. Internat. Atherosclerosis Society 2012, Sydney, Australia.
19. **Weber C** (2011) Chemokines and their receptors as therapeutic targets in atherosclerosis. EMBO Molecular Medicine Conference: Molecular Insights for Innovative Therapies, Heidelberg, Germany.
20. **Weber C** (2011) The inflammatory pathogenesis of atherosclerosis. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
21. **Weber C** (2011) MicroRNAs - a novel target in cardiovascular prevention. ESC, Paris, France.
22. **Weber C** (2011) Chemokines as therapeutic targets in the treatment of atherosclerosis. 79<sup>th</sup> European Atherosclerosis Society (EAS) Congress, Gothenburg, Sweden.
23. **Weber C** (2011) Microparticles as transfer modules in cardiovascular disease. 6th European Meeting for Vascular Biology & Medicine (EVBVM), Krakow, Poland.
24. **Weber C** (2011) Role of inflammation in atherosclerosis. 10<sup>th</sup> World Congress in Inflammation. Paris, France.
25. **Weber C** (2010) Chemokines in the vascular inflammatory response. ESC, Stockholm, Sweden.
26. **Weber C** (2010) Chemokines as therapeutic targets in atherosclerosis. Kern Conferences, Aspen, USA.
27. **Weber C** (2010) Chemokines as crucial drivers of macrophage and dendritic cell function in atherosclerosis. International Vascular Biology Meeting (IVBM) 2010, Los Angeles, USA.

28. **Weber C** (2010) A miRNA-mediated mechanism for functional chemokine induction. Gordon Research Conference on *Chemotactic Cytokines*, Il Ciocco, Italy.
29. **Weber C** (2010) Role of chemokines for cell migration during inflammation. 8<sup>th</sup> World Congress on Trauma, Shock, Inflammation and Sepsis - TSIS 2010, Munich, Germany.
30. **Weber C** (2009) Progenitor cell trafficking in the vascular wall. International Society of Thrombosis and Haemostasis (ISTH) Meeting 2009, Boston, USA.
31. **Weber C** (2009) Chemokines as therapeutic targets in atherosclerosis. International Atherosclerosis Society (IAS) Meeting 2009, Boston, USA.
32. **Weber C** (2008) MIF as a pseudo-chemokine in atherosclerosis. AHA Scientific Sessions, New Orleans, USA.
33. **Weber C** (2008) Structural basis and *in vivo* relevance of chemokine heteromerization. Gordon Research Conference on *Chemotactic Cytokines*, Aussois, France.
34. **Weber C** (2008) The monocyte: function and fate. European Society of Cardiology (ESC), Munich, Germany.
35. **Weber C** (2008) Functional diversity of chemokines and mononuclear cell subsets in atherosclerosis. 77<sup>th</sup> European Atherosclerosis Society (EAS) Congress, Istanbul, Turkey.
36. **Weber C** (2008) Chemokines and chemokine-like ligands in vascular inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008, Atlanta, USA.
37. **Weber C** (2008) Chemokine-like functions of MIF in leukocyte recruitment - Joint Lecture. Keystone Symposia Leukocyte Trafficking / Chemokines and Chemokine Receptors, Keystone, USA.
38. **Weber C** (2008) Chemokines: inflammatory mediators of atherosclerosis. 3<sup>rd</sup> Joint Meeting of French, German and Swiss Atherosclerosis Societies, St. Gervais, France.
39. **Weber C** (2007) Ambivalence of progenitor cells in vascular repair and plaque instability, Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands.
40. **Weber C** (2007) Role of EPCs in cardiovascular repair, European Society of Cardiology (ESC), Wien, Austria.
41. **Weber C** (2007) Basic Science Key Note - Cytokine in der Atherosklerose: Angriffspunkte für die therapeutische Intervention? 74<sup>th</sup> Annual Congress of the German Cardiac Society (DGK), Mannheim, Germany.
42. **Weber C** (2007) Chemokines & atherosclerosis, 7<sup>th</sup> World Congress Trauma, Shock, Inflammation & Sepsis TSIS 2007, Munich, Germany.
43. **Weber C** (2007) Platelet & inflammatory cell interactions. British Atherosclerosis Society, Glasgow, UK.
44. **Weber C** (2006) Cross-talk between blood cells in inflammation. European Society of Cardiology (ESC) and World Congress of Cardiology (WCC), Barcelona, Spain.
45. **Weber C** (2006) Chemokines in vascular cell recruitment, UK/German Adhesion Society, London, UK.
46. **Weber C** (2006) Chemokines in arterial pathology. Int. Vascular Biology Meeting, Amsterdam, Netherlands.
47. **Weber C** (2006) Cell-cell interactions in the vascular wall. III. Cardiovascular Healing Symposium, Leopoldina Akademie der Naturforscher, Würzburg, Germany.
48. **Weber C** (2005) Interplay of chemokines and platelets in vascular cell recruitment, 3<sup>rd</sup> European Vascular Biology Meeting (EVBM), Hamburg, Germany.
49. **Weber C** (2004) Platelet-derived mediators and atherosclerosis. AHA Scientific Sessions, New Orleans, USA.
50. **Weber C** (2004) Role of JAM-A in inflammatory & atherogenic leukocyte recruitment. Gordon Research Conference *Immunoglobulin Family Members in Infection, Immunity & Cancer*, Massachusetts, USA.
51. **Weber C** (2004) Role of chemokines in arteriogenesis and angiogenesis, Working Group Vascular Biology, 70<sup>th</sup> Annual Congress of the German Cardiac Society, Mannheim, Germany.
52. **Weber C** (2003) Novel molecular targets to modulate monocyte recruitment. Mario-Negri-Institute, Milan, Italy.
53. **Weber C** (2002) Involvement of JAM-1 as a newly identified ligand of LFA-1 in leukocyte transendothelial migration. 2<sup>nd</sup> Joint UK/German adhesion meeting, German Society of Immunology, Berlin, Germany.
54. **Weber C** (1998) Adhesion molecules, chemokines and the cytoskeleton in arteriosclerosis, Working group Pathogenesis Arteriosclerosis, 65<sup>th</sup> Annual Congress of the German Cardiac Society, Mannheim, Germany.

55. **Weber C** (1998) Antioxidant effects on monocyte-endothelial cell interactions & vascular cell apoptosis. FASEB Summer Research Conference *Mechanisms of Antioxidant Action*, Copper Mt., Colorado, USA.